Trust linked to IRADIMED CEO sells 7,500 shares
IRADIMED CORP director and CEO-related trust reports routine open-market sales of common stock.
Rhea-AI Filing Summary
IRADIMED CORP director and CEO-related trust reports routine open-market sales of common stock. The Phillip Susi 2008 Dynasty Trust sold a total of 7,500 shares of IRMD on March 30, 2026 in three transactions at weighted average prices of $94.81, $95.66 and $96.53 per share. After these trades, the Dynasty Trust holds 2,225,000 shares, while additional indirect holdings reported include 162,950 shares in the Roger E. Susi Revocable Trust and 2,062,500 shares in the Matthew Susi 2008 Dynasty Trust. The sales were carried out under a pre-arranged Rule 10b5-1 trading plan, and the reporting person disclaims beneficial ownership of the securities beyond his pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 7,500 shares
Net Sell
5 txns
Insider
Susi Roger E.
Role
CEO, President, Chairman
Sold
7,500 shs ($713K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 5,848 | $94.81 | $554K |
| Sale | Common Stock | 1,497 | $95.66 | $143K |
| Sale | Common Stock | 155 | $96.53 | $15K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 2,225,000 shares (Indirect, By Phillip Susi 2008 Dynasty Trust);
Common Stock — 162,950 shares (Indirect, By Roger E. Susi Revocable Trust);
Common Stock — 2,062,500 shares (Indirect, By Matthew Susi 2008 Dynasty Trust)
Footnotes (5)
- F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025.
- F2. This transaction was executed in multiple trades at prices ranging from $94.36 to $95.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3. This transaction was executed in multiple trades at prices ranging from $95.40 to $96.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $96.50 to $97.16. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.
Key Figures
Shares sold: 7,500 shares
Weighted average sale price 1: $94.81/share
Weighted average sale price 2: $95.66/share
+5 more
8 metrics
Shares sold
7,500 shares
Open-market sales on March 30, 2026
Weighted average sale price 1
$94.81/share
First sale tranche on March 30, 2026
Weighted average sale price 2
$95.66/share
Second sale tranche on March 30, 2026
Weighted average sale price 3
$96.53/share
Third sale tranche on March 30, 2026
Dynasty Trust holdings
2,225,000 shares
Phillip Susi 2008 Dynasty Trust after sales
Revocable Trust holdings
162,950 shares
Roger E. Susi Revocable Trust holding entry
Second Dynasty Trust holdings
2,062,500 shares
Matthew Susi 2008 Dynasty Trust holding entry
Net share change
-7,500 shares
Net-sell direction from transaction summary
Key Terms
Rule 10b5-1 trading plan, weighted average sale price, open-market sale, beneficial ownership, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"The price reported above reflects the weighted average sale price"
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
beneficial ownership regulatory
"The reporting person disclaims beneficial ownership of these securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Section 16 regulatory
"for purposes of Section 16 or for any other purpose"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did the IRADIMED (IRMD) Form 4 filed by Roger E. Susi report?
The Form 4 reports that a trust associated with IRADIMED CEO Roger E. Susi sold 7,500 shares of common stock. The transactions were open-market sales executed on March 30, 2026, and were made under a pre-arranged Rule 10b5-1 trading plan.
Were the IRADIMED (IRMD) insider sales discretionary or under a trading plan?
The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2025. Such plans schedule trades in advance, so the timing of these sales reflects the plan’s terms rather than day-to-day trading decisions by the insider.
AI-generated analysis. How Rhea-AI works. Not financial advice.
